Cytek Biosciences, Inc. · NASDAQ:CTKB
Cytek Biosciences — Q3 2025 Earnings Presentation
12 slides from Cytek Biosciences's earnings presentation, Nov 5, 2025
Slide 1: Q3 2025 Earnings Presentation
Q3 2025 Earnings Presentation November 5, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s future financial performance, including its outlook
Slide 3: Q3 2025 Revenue
Q3 2025 Revenue1 Product Revenue Service Revenue Q3 2025 Commentary (Y/Y) $57.5 • Total revenue increased 2% Y/Y $51.5 $52.3 $45.6 • Growth in the quarter was driven $41.5 by strong double-digit growth in APAC2 and from continued growth $39.5 $45.0 $38.1 in our recurring revenue $28.1 $31.4 business
Slide 4: Revenue by Geographic Region
Revenue by Geographic Region1 Q3 2025 Commentary (Y/Y) • US: Revenue was up 12% driven by $57.5 growth in pharma/biotech and service, $51.5 $52.3 offset by academic/government $45.6 $41.5 • EMEA: Revenue declined 28% driven by weakness in academic/government, partially offset by pharma/biotech and s
Slide 5: Strong revenue growth worldwide, excluding EMEA Instruments
Strong revenue growth worldwide, excluding EMEA Instruments1 $51.5 $52.3 11% Y/Y Growth Q3 2024 Q3 2025 WW Revenue excl. EMEA Instruments EMEA Instruments 1EMEA = Europe, Middle East & Africa 5
Slide 6: Strong Execution Across Growth Pillars Q3 2025
Strong Execution Across Growth Pillars Q3 2025 Instruments Bioinformatics Applications Clinical1 Expanded to a total installed base of 3,456 Cytek instruments, adding 161 units in Q3 2025 Expanded Cytek Cloud Users to over 22.6K users in the third quarter, growing base by 40% since the start of the
Slide 7: Q3 2025 Financial Overview
Q3 2025 Financial Overview in millions Q3 2025 Q3 2024 Y/Y Total Revenue $52.3 $51.5 2% Product $38.1 $39.5 (4)% Service $14.2 $12.0 19% Gross Profit $27.6 $29.0 (5)% Gross Margin 53% 56% Operating Expenses $36.7 $33.3 10% Loss from Operations ($9.2) ($4.2) NM Net Income/(Loss) $(5.5) $0.9 NM Non-GA
Slide 8: Reaffirming Full Year 2025 Revenue Guidance
Reaffirming Full Year 2025 Revenue Guidance FY 2025 Revenue1 $196 - $205 -2 to +2% y/y growth 1. Assumes no change from current currency exchange rates 8
Slide 9: Well-positioned for Growth and Profitability
Well-positioned for Growth and Profitability Technology Platform Leader Strengthening market leadership position through targeted investments that will reinforce our competitive position and accelerate growth Global Diversification Multiple geographies with instrument and recurring revenue streams G
Slide 10: Appendix
Appendix 10
Slide 11: Reconciliation of GAAP to Non-GAAP Measures (Unaudited)
Reconciliation of GAAP to Non-GAAP Measures (Unaudited) (In thousands) Three months ended September 30, 2025 September 30, 2024 (Unaudited) (Unaudited) GAAP Gross profit $ 27,551 $ 29,005 Stock based compensation $ 906 $ 1,154 Amortization of acquisition-related intangible assets $ 481 $ 492 Non-GAA
Slide 12: Thank You
Thank You 12